Latest news with #Deglusterol
Business Standard
01-08-2025
- Health
- Business Standard
Health and Wellness Entrepreneur Sak Narwal Talks Oral Peptides - A Simpler Path to Metabolic Wellness
PNN New Delhi [India], August 1: Sak Narwal is a prominent health and wellness entrepreneur, recognized as a global wellness ambassador and a significant voice in the health and wellness industry. He is the CEO and founder of eSensorem, a metabolic health device and platform delivering continuous, non-invasive health insights as a path to proactive, preventative wellness. His work focuses on making innovative health solutions, particularly in metabolic wellness, more accessible and convenient for the general population, which is why he is now highlighting oral peptides as a groundbreaking advancement. Narwal highlights oral peptides, particularly Deglusterol in ProGsterol, as a breakthrough in metabolic wellness. This innovative approach aims to simplify daily metabolic health management, offering benefits like hunger control, glucose regulation, and enhanced fat utilization without injections. Narwal emphasizes making healthier options more convenient for the general population, a goal oral peptides are poised to achieve. Metabolic health, encompassing food breakdown, blood sugar maintenance, and energy storage, has traditionally relied on often inconvenient injectable therapies and oral medications with side effects. However, advancements in delivery systems are changing this, leveraging peptides' role as potent body messengers and cellular communicators. ProGsterol, containing the synthetic peptide Deglusterol, marks a significant milestone as the world's first synthetic peptide to receive NDI (New Dietary Ingredient) approval from the U.S. FDA. As Narwal explains: 'Deglusterol is designed to address common metabolic disorders like obesity and Type 2 Diabetes Mellitus. Its primary function is to enhance insulin sensitivity, helping the body better manage glucose levels. Furthermore, Deglusterol shows potential in mitigating fatty liver disease, particularly non-alcoholic fatty liver disease (NAFLD), which is a rising concern linked to obesity. ProGsterol, with Deglusterol inside, is considered a key solution for metabolic syndrome, impacting the central nervous system, heart/blood vessels, pancreatic islets, liver, ovary, and adipose tissue.' The core benefits of oral peptides like Deglusterol include: * Appetite and Satiety: Some of the peptides leave one feeling quite full and reduce appetites. They do so by stimulating the gut in a way that makes the brain realize that it is time to stop eating; hormones are released which makes it easy to adhere to a healthy diet. * Balanced Blood Sugar: Deglusterol increases adiponectin levels, boosts insulin receptor sensitivity, activates AMPK, and reduces inflammatory markers, leading to better glucose management. Clinical trials demonstrate significant improvements in fasting blood glucose, HbA1C, and HOMA-IR in Type II Diabetes and pre-diabetes patients. * Fat Utilization: These peptides help the body more effectively use fat for energy, supporting weight loss through enhanced fat metabolism and thermogenesis. It has been observed to lead to body weight loss and protect against liver damage in DIO NAFLD animal models. Deglusterol has shown efficacy in weight control and anti-obesity effects in animal models and human clinical studies, improving metrics like Waist-Hip Ratio (WHR), body weight, and BMI. It also inhibits fat accumulation and promotes fat breakdown at a cellular level. Overcoming digestive enzyme breakdown, researchers have developed special coatings, helper molecules, and tiny capsules for successful oral delivery. Narwal states, "While there's many supplements and injectables on the market for managing metabolic health, accessibility, efficacy and side-effects are all major barriers for consumers. Oral peptides bypass the barriers, providing a more affordable, safe, and easy to take alternative that is accessible to the people who truly need it. This is the change that the health and wellness industry has been waiting for." A critical advantage of ProGsterol over many existing Type 2 Diabetes medications is its favorable safety profile. Clinical trials have reported no observed hypoglycemia or any other side effects in consumers. It does not cause hypoglycemia, gastrointestinal side effects, or sexual dysfunction. Furthermore, it is reported to be safe for individuals with cardiovascular or renal disorders, with no cardiovascular side effects reported. Being a peptide product made of amino acids, it is designed to be compatible with the body and free of chemical drug side effects. This distinguishes ProGsterol, as while other oral medications like Metformin exist, they can come with a range of side effects. Significantly, recent research suggests that Metformin can even blunt or inhibit exercise-induced improvements in insulin sensitivity and cardiorespiratory fitness, and may reduce gains in lean muscle mass, which can be a major drawback for athletes seeking to optimize their performance and physical adaptations to training. While Narwal maintains that "there is not yet a magic pill", ProGsterol's promising clinical outcomes and superior safety profile suggest it is the most advanced "pill-based method of keeping our metabolism active" that integrates seamlessly into daily life without injections, inconvenience, or discomfort. This oral peptide could empower millions to better manage their metabolic health
Time of India
21-04-2025
- Health
- Time of India
Documents reveal modus operandi of illegal clinical trials at VS Hospital
Ahmedabad: How did a team of contracted doctors, along with an associate professor, collude with a city-based firm to conduct allegedly illegal clinical trials at VS Hospital, which remained undetected for four years? Fresh documents, including the clinical trial agreement (CTA) for a drug trial involving Deglusterol for an east Asian pharma company, accessed by the investigating committee, provides a clear picture. Documents accessed by TOI reveal that one such clinical trial study was titled, "A randomized, double-blind, placebo-controlled, parallel study to assess the effects of Deglusterol on fasting glucose and other cardiometabolic risk factors in patients with Type 2 diabetes mellitus" under protocol number CG-D-P02. "Protocol numbers for drug trials are assigned by the Central Drugs Standard Control Organization (CDSCO)," said a senior AMC official. "The doctors knew that an ethics committee was formed at SVP Hospital but not at VS Hospital after the 2019 split in the management. Dr Devang Rana and eight contracted doctors exploited this gap for execution," a committee member alleged. The trial was structured through a CTA involving the sponsor, an east Asian pharma company, a city-based contract research organization (CRO), principal investigator Dr Dhaiwat Shukla, VS General Hospital (the trial site), and a site management organization based out of Jagatpur. "Shukla was among the eight contracted doctors whose services were terminated in this alleged drug trial case," says The pharma firm, as the sponsor, supplied Deglusterol free of cost and delegated operational control to the city based CRO. "The CRO's responsibilities included overseeing trial execution, monitoring data collection, managing communication with the ethics committee and coordinating financial transactions with the investigator and institution," said a senior AMC official. He added, "The CRO entered into direct agreements with Dr Shukla at VS General Hospital. Dr Shukla was tasked with ensuring compliance with Good Clinical Practice (GCP) guidelines. He was responsible for submitting the trial protocol, the final CTA, insurance documents and CTRI registration to the Jodhpur -based hospital's ethics committee — designated as the approving body stated the CTA agreement." "Once enrolled, patients were administered the investigational drug in accordance with the protocol. Data related to each subject, including medical notes and trial progress, was entered into a third-party platform, with the CRO maintaining monitoring rights. The investigational drug was stored, handled and administered under the supervision of the principal investigator, and any adverse reactions were to be reported to the CRO, the sponsor and the ethics committee," the AMC official said.
